Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …

Objective In patients suffering multiple sclerosis activity despite treatment with interferon β or
glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod …

Secondary progressive multiple sclerosis (MS) is typically defined as deterioration
independent of relapses for≥ 6 months following an initial relapsing–remitting course; …

Background: We conducted this study to estimated the time of conversion from relapsing-
remitting MS (RRMS) to SPMS and its early predictor factors. Methods: In this retrospective …

Importance After multiple sclerosis (MS) relapse while a patient is receiving an injectable
disease-modifying drug, many physicians advocate therapy switch, but the relative …

Importance Treatment strategies for relapsing-remitting multiple sclerosis (RRMS) vary
markedly between Denmark and Sweden. The difference in the association of these national …

Background Multiple sclerosis typically has onset in young adults and new disease activity
diminishes with age. Most clinical trials of disease-modifying therapies for multiple sclerosis …

Background Approximately one-third of patients with multiple sclerosis (MS) are
unresponsive to, or intolerant of, interferon (IFN) therapy, prompting a switch to other …

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by
insidious disability worsening that is independent from clinically apparent relapses and is …